gastric cancer
Conditions
Interventions
ENEVO administration for 24weeks
ENEVO administration for 2weeks
Sponsors
Fujita Health University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)The patient who diagnosed with histologically gastric cancer. 2)The patient who is more than 20 years old to below 75 years old. 3)The patient who received no existing treatment(including neoadjuvant chemotherapy) and are scheduled surgery in primary resection. 4)The patient who is PS(ECOG) from 0-2. 5)The patient who can be oral ingestion. 6)The patient who can obtain informed consent. 7)The patient who can write a diary exactly.
Exclusion criteria
Exclusion criteria: 1)The patient who are overlapped cancer of synchronism or metachronous, or who are multiple cancer. 2)The patient who contraindicated of ENEVO. 3)The patient who are participating in other clinical trials. 4)The patient who is not suitable for this clinical study by researchers. 5)The patient who experienced severe postoperative complications(more than Grade3 of Clavien-Dindo classification).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The body weight loss rate as compared to preoperative body weight at 24weeks after beginning to take ENEVO. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The body weight loss rate as compared to preoperative body weight at 52weeks after beginning to take ENEVO . 2.The maximum body weight loss rate as compared to preoperative body weight. 3.Nutritional assessment. 4.Incidence of adverse events. 5.In case of adjuvant chemotherapy,treatment completion rate. | — |
Countries
Japan
Contacts
Public ContactMiyuki Ueno
Fujita Health University Department of clinical pharmacy
Outcome results
None listed